Key Players In The Human Microbiome Market & Growth Strategies Adopted By Them

By Author: marketsandmarkets
Total Articles: 82
Comment this article

Overview of This Study:

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global human microbiome market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The human microbiome market's size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Recent Developments in the Global Human Microbiome Market:

# In 2022, OptiBiotix Health Plc. signed an exclusive sales and distribution agreement with Nahdi Medical Co. To help tackle the obesity epidemic, the company’s GoFigure and SlimBiome Medical weight management products will be available in the KSA from early 2022 through the new agreement with Nahdi.

# In 2020, 4D pharma merged with ...
... Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will support and accelerate the ongoing development of 4D pharma’s Live Biotherapeutic. Live Biotherapeutics is a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment, or cure of a disease.

# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds

Major Growth Driving Factors:

Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period.

However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Opportunity: Increasing collaborations between public-private organizations

With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies so as to study microbiomes in the hope of identifying new drugs and drug targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders are focusing on strategic collaborations and partnerships to increase their product pipelines with well-organized research and development techniques. In the last two years, there have been several collaborations and partnerships involving major companies.

Global Key Players:

The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US), 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).

Growth Strategies Adopted by Them:

Various growth strategies have been adopted by these players, such as agreements, collaborations, partnerships, and acquisitions to increase their presence in the global human microbiome market.

Enterome Bioscience (France) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat microbiome-associated diseases with a focus on IBDs, Crohn’s, and cancer (glioblastoma, colon, pancreatic, lung, and breast) indications. To sustain its position in the human microbiome market, ENTEROME adopts various organic and inorganic growth strategies.

The company has been consistently entering into agreements and partnerships with strong biopharmaceutical players, which will help it to expedite drug development for cancer and GI disorders. In 2021, the company raised USD 113.5 million (EUR 96 million) in a Series D financing, which will be used for clinical trials of Enterome’s lead development programs

Seres Therapeutics (US) is one of the emerging players operating in this market. The company is engaged in developing a range of novel therapeutic products based on the human microbiome. To sustain its position in the human microbiome market, Seres Therapeutics focuses on its products offered for the market. The company’s microbiome therapeutics platform allows to significantly reduces the time typically required to advance therapeutics to the clinic, and ultimately, to the market. The company’s SER-109 program for the treatment of recurrent C difficile infection is anticipated to be the first-ever FDA-approved microbiome therapy. This has helped the company to strengthen its market position in high-growth niche opportunities.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=69695102

Major Revenue Growth Expectations:

The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029.